Brodalumab
- Generic Name
- Brodalumab
- Brand Names
- Siliq, Kyntheum
- Drug Type
- Biotech
- CAS Number
- 1174395-19-7
- Unique Ingredient Identifier
- 6ZA31Y954Z
Overview
Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Background
Brodalumab has been used in trials studying the treatment of Asthma, Psoriasis, Crohn's Disease, Psoriatic Arthritis, and Rheumatoid Arthritis. Brodalumab was FDA approved in February, 2017 as Siliq for the treatment of moderate-to-severe plaque psoriasis.
Indication
Brodalumab has been approved for the treatment of psoriasis vulgaris, psoriatic arthritis, pustular psoriasis and psoriatic erythroderma.
Associated Conditions
- Severe Plaque psoriasis
- Moderate Plaque psoriasis
Clinical Trials
FDA Approved Products
Siliq
Manufacturer:Bausch Health US LLC
Route:SUBCUTANEOUS
Strength:210 mg in 1 1
Approved: 2023/09/01
NDC:0187-0004
Singapore Approved Products
No Singapore products found for this drug
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.
© Copyright 2025. All Rights Reserved by MedPath